7 completed, 2 terminated. 6 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Zofran ODT: new trials by email Literature Review of Zofran ODT trials Research Report on Zofran ODT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas LMP744, Ondansetron, Olanzapine - Solid Tumors, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2017-02-27 | 2024-12-10 |
| Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine - Locally Advanced Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2016-10-12 | 2021-08-09 |
| Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion - Breast - Female | Phase 3 | Completed | Stanford University | 120 | 2015-11-01 | 2021-09-23 |
| Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers Ondansetron, Ondansetron + Hylenex, Zofran ODT - Healthy | Phase 1 | Completed | Halozyme Therapeutics | 12 | 2012-02-01 | 2014-01-24 |
| Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions Ondansetron, Zofran ODT - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 24 | 2003-11-01 | 2008-04-16 |
| Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions Ondansetron, Zofran - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 24 | 2003-10-01 | 2008-04-16 |
| Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions Ondansetron, Zofran - Healthy | Phase 1 | Completed | Par Pharmaceutical, Inc. | 18 | 2002-08-01 | 2008-04-11 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Fasting (2) · Burkitt Lymphoma (1) · Carcinoma (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (3) · Par Pharmaceutical, Inc. (3) · Halozyme Therapeutics (1) · M.D. Anderson Cancer Center (1) · Stanford University (1)
United States (6) · Canada (2)
Christian Aumais (2) · Alice P Chen, M.D. (1) · Eric Sicard (1) · Gordon K Lee, MD (1) · Mark J Roschewski, M.D. (1) · Samuel S Dychter, MD (1) · Saroj Vadhan (1) · Scott M Norberg, D.O. (1)
PMID 23574119, PMID 24224624, PMID 24486335, PMID 25024303, PMID 29748435, PMID 30125215, PMID 34432874, PMID 35882475, PMID 40439882